Skip to content



What do you think about BMC? Take part in

New Content Item

HIV cure – what does it mean?

In honor of World AIDS Day 2017, Dr Andrew Lever discusses the possibilities and complexities of a cure for HIV in this BMC On Medicine blog.

December 1st 2017 is the 30th anniversary of World AIDS Day. This year's theme is “Increasing Impact through Transparency, Accountability, and Partnerships”, reflecting how to increase our impact to move epidemics from crisis toward control. 
Read more from across BMC


  1. Content type: Research


    Authors: Delia M. Pinto-Santini, Carolyn R. Stenbak and Maxine L. Linial

View all articles
  1. Content type: Short report


    Authors: Jintanat Ananworanich, James LK Fletcher, Suteeraporn Pinyakorn, Frits van Griensven, Claire Vandergeeten, Alexandra Schuetz, Tippawan Pankam, Rapee Trichavaroj, Siriwat Akapirat, Nitiya Chomchey, Praphan Phanuphak, Nicolas Chomont, Nelson L Michael, Jerome H Kim and Mark de Souza

View all articles

Journal news

Stay up-to-date with the latest news and announcements from the Editors of Retrovirology.

Read more

Andrew Lever, University of Cambridge, UK
Johnson Mak, Institute for Glycomics, Griffith University, Australia 

Founding Editor
Kuan-Teh Jeang, National Institutes of Health, USA

Aims and scope

Retrovirology is an open access, online journal that publishes stringently peer-reviewed, high-impact articles on host-pathogen interactions, fundamental mechanisms of replication, immune defenses, animal models, and clinical science relating to retroviruses. Retroviruses are pleiotropically found in animals. Well-described examples include avian, murine and primate retroviruses. 

Two human retroviruses are especially important pathogens. These are the human immunodeficiency virus, HIV, and the human T-cell leukemia virus, HTLV. HIV causes AIDS while HTLV-1 is the etiological agent for adult T-cell leukemia and HTLV-1-associated myelopathy/tropical spastic paraparesis. Retrovirology aims to cover comprehensively all aspects of human and animal retrovirus research.

Latest Tweets

Editor profiles

Andrew Lever

Andrew Lever, Editor-in-Chief

Professor Lever graduated in Biochemistry and Medicine from the University of Wales and undertook postgraduate training in clinical medicine there and in London and Newcastle. He took a Doctorate in Immunology studying patients with immunodeficiency at the MRC Clinical Research Centre in London and further developed his interests in the balance between infectious agents and the immune system with a Lectureship funded by the Wellcome Trust at the Royal Free Hospital in London studying viral hepatitis and cytomegalovirus infection. His research on HIV began in Boston with Dr Joe Sodroski where he began work on studying the mechanism of RNA encapsidation of retroviruses. He returned to a Senior Lecturer post at St George’s Hospital, London and moved subsequently to the University of Cambridge, where he was awarded a Personal Chair in Infectious Diseases in 2000. His research on retroviruses involves studies of the biology and fate of the genomic RNA in lentiviruses and allied work on lentivirus-based vectors and HIV latency, subjects which are core to Retrovirology.

New Content Item

Johnson Mak, Editor-in-Chief

Professor Mak is a native of Hong Kong who undertook his undergraduate and post-graduate training at McGill University in Montreal, Canada. During his PhD Johnson worked with Professor Lawrence Kleiman at the McGill AIDS Centre studying packaging of primer tRNA into HIV. He subsequently moved to Melbourne, Australia to continue work on HIV assembly at the Burnet Institute under the guidance of Professor Suzanne Crowe. He is currently a Professor at the Institute for Glycomics, Griffith University, Gold Coast. He has a broad research portfolio in HIV having studied primer tRNAs in retroviruses, genomic RNA packaging and dimerization, cholesterol and lipids in HIV, viral-host interactions, imaging of HIV and analysis of recombination and mutation in HIV using next generation sequencing. His team pioneered the production of full-length recombinant HIV Gag for biochemical and biophysical analyses of HIV assembly. Recently Johnson and his team have described a pre-entry priming process for HIV.